Your hospital provides the operating theatre, andrology lab, existing IUI programme and patient base. Eve provides EVEA™, protocols, training and regulatory infrastructure. Result: an additional ART pathway without the capital and infrastructure requirements of a conventional IVF laboratory.
Eve works with hospital systems and fertility operators across Asia-Pacific — providing the device, protocols, training and quality systems to run an intravaginal-culture service line. Our model is recurring: Eve earns per-cycle, aligned with partner success.
Add an intravaginal-culture service line without the capital and infrastructure burden of a conventional IVF lab. No cleanroom. No incubator bank.
Launch an IVC service line in secondary cities and underserved regions through existing healthcare infrastructure — without requiring a conventional embryology laboratory.
Manage device supply, regulatory licensing and customer relationship in key territories. Eve provides backend support and clinical training.
Eve is in active discussions with hospital systems and distributors across the region — secondary-city medical centres, fertility networks and regional health systems where conventional embryology infrastructure is not available. Details of active partnerships and deployments are shared under confidentiality agreements with clinical and regulatory partners.
Operating theatre, andrology lab, embryology staff, existing IUI programme, patient access.
EVEA™ device, clinical protocols, staff training, quality systems, regulatory documentation.
Add an advanced ART pathway. Serve more patients. Retain clinical and economic ownership. No conventional IVF laboratory required.
Map your current IUI volume, referral patterns and patient base. Weeks 1–4.
Confirm your existing theatre, andrology and OB/GYN setup against IVC requirements. Weeks 3–6.
Full clinical dossier and hands-on clinical training via a US training partner. Weeks 6–12.
Define patient-selection criteria, protocol and success metrics. Weeks 12–16.
We work with hospital groups evaluating lower-infrastructure fertility programmes for underserved regional markets.
Request a hospital deployment discussion → Request the clinical & regulatory dossier